Aprea Therapeutics, Inc.
APRE · NASDAQ
12/31/2024 | 12/31/2023 | 12/31/2022 | 12/31/2021 | |
|---|---|---|---|---|
| Valuation | ||||
| PEG Ratio | 0.03 | 0.01 | -0.00 | 0.05 |
| FCF Yield | -74.87% | -72.17% | -4,560.08% | -61.69% |
| EV / EBITDA | 0.37 | 0.32 | 0.25 | -0.22 |
| Quality | ||||
| ROIC | -69.45% | -84.71% | -276.74% | -73.87% |
| Gross Margin | 98.51% | 98.79% | 0.00% | 0.00% |
| Cash Conversion Ratio | 1.05 | 0.85 | 0.22 | 1.02 |
| Growth | ||||
| Revenue 3-Year CAGR | – | – | – | – |
| Free Cash Flow Growth | -10.61% | 50.94% | 33.63% | 9.90% |
| Safety | ||||
| Net Debt / EBITDA | 1.77 | 1.51 | 0.26 | 1.43 |
| Interest Coverage | 0.00 | 0.00 | -83.30 | 0.00 |
| Efficiency | ||||
| Inventory Turnover | 0.00 | 0.00 | 0.00 | 0.00 |
| Cash Conversion Cycle | -22,115.23 | -86,455.57 | -1,649.84 | -2,382.08 |